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Abstract
Background: To date, the use of traditional nucleic acid amplification tests (NAAT) for detection of HIV-1 DNA or RNA has
been restricted to laboratory settings due to time, equipment, and technical expertise requirements. The availability of a
rapid NAAT with applicability for resource-limited or point-of-care (POC) settings would fill a great need in HIV diagnostics,
allowing for timely diagnosis or confirmation of infection status, as well as facilitating the diagnosis of acute infection,
screening and evaluation of infants born to HIV-infected mothers. Isothermal amplification methods, such as reverse-
transcription, loop-mediated isothermal amplification (RT-LAMP), exhibit characteristics that are ideal for POC settings, since
they are typically quicker, easier to perform, and allow for integration into low-tech, portable heating devices.
Methodology/Significant Findings: In this study, we evaluated the HIV-1 RT-LAMP assay using portable, non-instrumented
nucleic acid amplification (NINA) heating devices that generate heat from the exothermic reaction of calcium oxide and
water. The NINA heating devices exhibited stable temperatures throughout the amplification reaction and consistent
amplification results between three separate devices and a thermalcycler. The performance of the NINA heaters was
validated using whole blood specimens from HIV-1 infected patients.
Conclusion: The RT-LAMP isothermal amplification method used in conjunction with a chemical heating device provides a
portable, rapid and robust NAAT platform that has the potential to facilitate HIV-1 testing in resource-limited settings and
POC.
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Introduction
HIV-1diagnostictestsare held toa high standardofperformance,
as diagnosis has a direct impact on patient care and reduction of
transmission. Despite technological advances in the field of HIV
diagnostics and the high sensitivity and specificity associated with
most HIV diagnostic tests that are currently available, it is estimated
that approximately 20% of HIV-infected individuals living in the
United States remain undiagnosed [1]. Furthermore, testing sites
have reported as many as 35 to 50% of individuals with an initial
positive test result will not return for a confirmatory diagnosis if
follow-up laboratory testing is required [2]. Rapid HIV antibody-
based tests, which can be performed with minimal training and
typically provide results in under 30 minutes [3], have facilitated
HIV testing at the point-of-care and subsequently increased the
numbers of individuals aware of their serostatus [4]. Rapid tests are
currently a key component of HIV screening at the point-of-care
(POC), significantly expanding the diagnostic capabilities of testing
sites in developed countries, as well as resource-limited settings.
Despite the advances made by the widespread availability of
rapid tests, all antibody-based tests for the detection of HIV exhibit
some limitations. HIV-specific antibody typically begins to appear
around three weeks post-infection, allowing for detection by most
antibody-based assays within 3–6 weeks [3,5]. The window of time
prior to or during early seroconversion may lead to false-negative
test results in recently infected individuals. Additionally, accurate
diagnosis of infants born to HIV-infected mothers can be
challenging if based solely on antibody positivity, since vertically
transferred maternal antibodies may persist for 12–18 months
after birth [6,7]. For confirmatory diagnosis of early HIV infection
or infant diagnosis, nucleic acid amplification tests (NAAT) are
preferred, as HIV-1 RNA can be detected as early as 10–12 days
post infection and HIV-1 DNA and/or RNA are definitive
indicators of active infection [5]. In their current form, however,
NAAT’s are not feasible for POC testing, because they are time-
consuming, expensive, and technically complicated. To date, the
Aptima HIV-1 RNA assay (Gen-Probe, Inc., http://www.fda.gov/
BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/
LicensedProductsBLAs/BloodDonorScreening/InfectiousDisease/
UCM080466) is the only FDA-approved NAATfor the diagnosisor
confirmationofHIV-1infection and itis only suitableforlaboratory
testing.
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NAAT that can be performed with minimal training, limited
equipment, and a relatively short turnaround time (,1 hour)is
desirable [8]. The development of a rapid NAAT has proven to be
especially challenging since the technology involved in simplifying
the test procedure often equates to increased equipment and
material costs [8]. Additionally, the reduction in technical
complexity should not compromise test sensitivity and specificity.
For increased applicability at the POC, an increasing number of
novel isothermal amplification techniques have been developed
[9]. Isothermal amplification is an attractive alternative to
traditional PCR or RT-PCR since thermalcycling is not required,
allowing for greater versatility in terms of heating or amplification
devices. One such amplification method, termed Loop-Mediated
Isothermal Amplification (LAMP) [10], has been optimized for the
detection of DNA and/or RNA (RT-LAMP) from a wide range of
bacterial and viral pathogens [11,12,13,14,15,16,17,18,19], in-
cluding HIV [20,21].
LAMP or RT-LAMP exhibits several characteristics that are
ideal for integration into a rapid nucleic-acid based diagnostic test.
The amplification reaction requires six primers specific for eight
separate regions within the target sequence, contributing to the
high specificity of the amplification method. Amplified material
can typically be detected within 15–60 minutes when incubated at
a constant reaction temperature of 60–65uC [22]. LAMP has also
proven to be less sensitive to biological inhibitors than PCR
[23,24], which enables direct amplification from clinical speci-
mens, thereby eliminating the need for an additional nucleic acid
extraction step. Direct amplification from plasma, whole blood,
and oral fluid has previously been demonstrated for HIV-1
[20,21,25]. Lastly, immediate visual detection of amplified
products is facilitated by the large amount of DNA that is
generated by each reaction. Several groups have incorporated
fluorescent detection methods into the LAMP assay for real-time
or immediate naked-eye detection [15,17,21,22,26].
The simplicity and isothermal nature of the LAMP procedure
opens the door for the evaluation of low-tech integrated devices or
novel heating elements, which are appropriate for low-resource
settings, where costly equipment and electricity cannot be
obtained. In this study, the HIV-1 RT-LAMP assay was evaluated
using portable, non-instrumented nucleic acid amplification
(NINA) devices that generate heat from the exothermic reaction
of calcium oxide and water [27,28]. We demonstrated the
temperature stability of the NINA heating devices and feasibility
for POC testing of whole blood specimens from HIV-1 infected
individuals.
Materials and Methods
Non-instrumented nucleic acid (NINA) heaters
Prototype NINA heaters were designed and provided by
Program for Appropriate Technology in Health (PATH, Seattle,
WA), as described [27,28]. Briefly, an amplification temperature of
approximately 60uC was provided by the exothermic reaction of
calcium oxide (CaO; Sigma-Aldrich, St. Louis, MO) and water.
The heating devices, containing the chemical reaction, were
designed using thermally insulated, stainless-steel canisters with
plastic screw-top lids (Fig. 1). The lids were modified to contain
three sample wells that fit standard 200 ml PCR tubes and were
filled with a proprietary phase-change material (PCM) that was
used to buffer the heat derived from the exothermic reaction,
thereby providing a constant temperature. Lastly, plastic caps
containing foam insulation were designed to fit on the top of the
canister lids. The thermal profiles of the sample wells were
measured and recorded using a digital thermometer (DaqPRO
5300 Data recorder; OMEGA Engineering, Inc., Stamford, CT).
Linearity panels and clinical specimens
DNA and RNA linearity panels were prepared to determine the
sensitivity of the HIV-specific RT-LAMP assay. A DNA panel was
generated from DNA extracted from the human monocytic cell
line OM-10.1 [29], using a QIAamp DNA blood mini kit
(QIAGEN, Valencia, CA). Cell count was used to quantify the
input DNA copy number, as a single integrated provirus is
contained in each cell [29]. The extracted DNA was diluted ten-
fold in RNase-free water to create a linearity panel, ranging from
10
5 copies/ml to 10
3 copies/ml. An RNA linearity panel was
obtained commercially (PRD801; SeraCare Life Sciences, Mil-
Figure 1. NINA heating devices with DaqPRO 5300 Data recorder.
doi:10.1371/journal.pone.0031432.g001
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6 copies/ml to 8 copies/ml, as
determined by Roche AMPLICOR HIV MONITOR
TM v 1.5,
Bayer VERSANT HIV-1 RNA bDNA 3.0 Assay, bioMerieux
NucliSensH HIV-1 QT, and Abbott Real Time HIV-1 m2000
TM.
RNA was extracted from the panel members using a Viral RNA
mini kit (QIAGEN). Negative controls included DNA extracted
from PBMC infected with HIV-2 SLRHC [30] and RNA
extracted from HIV-2 NIH-Z purified virus (Advanced Biotech-
nologies Inc., Columbia, MD).
Whole blood from HIV-1 infected individuals was collected as
part of a separate, IRB-approved study [31], or obtained
commercially (SeraCare Life Sciences). All HIV-positive samples
were confirmed using the following tests: Genetic Systems HIV-1/
HIV-2 plus O EIA (Bio-Rad Laboratories, Redmond, WA), GS
HIV-1 Western blot (Bio-Rad Laboratories), Aptima HIV-1 RNA
assay (Gen-Probe, Inc., San Diego, CA), and Amplicor HIV-1
DNA assay (Roche Diagnostics, Branchburg, NJ ). Viral and
proviral loads are unknown, since the samples were tested with
qualitative, nucleic acid-based assays. All clinical specimens
evaluated in this study were obtained from individuals infected
with subtype B HIV-1 virus. As a negative control, HIV-1
seronegative blood samples (SeraCare Life Sciences) were included
in every experiment involving whole blood. A positive control
included HIV-1 seronegative blood spiked with 5610
6 virus
particles/ml of HIV-1 BaL (Advanced Biotechnologies Inc.).
RT-LAMP primer design
HIV-1-specific RT-LAMP primers were designed to recognize a
conserved sequence within the reverse transcriptase (RT) gene. The
six primers required for the RT-LAMP reaction, forward outer (F3),
backwardouter(B3),forwardinner(FIP),backwardinner(BIP),and
the loop primers (LoopF and LoopB), were designed using the
PrimerExplorer V4 software (Eiken Chemical Co. Ltd.; http://
primerexplorer.jp/e/). The LAMP primers and amplification cycle
have been described in detail by Nagamine et al. [32]. Additional
modifications included a linker sequence of four thymidines inserted
between the F2 and F1c sequences of the FIP primer, as described
[20], and the addition of the fluorescent molecule HEX to the 59
end of the LoopF primer. The labeled primer, along with a
quencherprobe,allowedforimmediatevisualdetectionofamplified
products [21]. The quencher probe consisted of the complementary
sequence of the LoopF primer with Black Hole Quencher-1 (BHQ-
1) added to the 39 end. The HIV-1 HXB2 sequence (GenBank
accession number AF033819) was used as the reference for
generating the RT-LAMP primers. The sequences of the HIV-1
RT-specific primers and quencher are listed in Table 1.
RT-LAMP reaction
The RT-LAMP reaction was performed using the following
reaction mix: 0.2 mM (final concentration) of each F3 and B3
primers, 1.6 mM of each FIP and BIP primers, 0.8 mM of each
LoopF and HEX-LoopB primers, 0.8 M betaine (Sigma-Aldrich),
10 mM MgSO4, 1.4 mM dNTPs, 16ThermoPol reaction buffer
(New England Biolabs, Ipswich, MA), 16 U Bst DNA polymerase
(New England Biolabs) and 2 U AMV reverse transcriptase
(Invitrogen, Carlsbad, CA). The reaction was carried out in a total
volume of 25 ml for amplification of extracted nucleic acid, 10 ml
of which constituted the sample. For amplification of whole blood
specimens, a 100 ml reaction volume was used to facilitate visual
detection of amplified products. Whole blood was added directly
into the reaction at a total volume of 40 ml, following a 1:4 dilution
with red blood cell lysis buffer (2.5 mM KHCO3, 37.5 mM
NH4Cl, and 0.025 mM EDTA), as previously described [21]. The
reaction mixture was incubated at 60uC for 60 minutes, using a
GeneAmpH PCR System (Applied Biosystems, Foster City, CA) or
the NINA heaters. For reactions amplified in the thermalcylcer, an
additional two minute heating step of 80uC was added at the end
of the amplification cycle to terminate the reaction.
The reaction tubes were evaluated for the presence of
amplification, following addition of the quencher probe at a 2:1
ratio of quencher to labeled-primer, as previously described [21].
Amplification was determined visually by observing fluorescence
in the reaction tubes, using the UV lamp from a ChemiDoc XRS
system (Bio-Rad Laboratories, Hercules, CA). Amplification was
confirmed by electrophoresis using a 1.2% agarose gel containing
SYBRH Safe gel stain (Invitrogen), which was subsequently
visualized using the ChemiDoc XRS system.
RT-LAMP in NINA heaters
To compare temperature and amplification consistency, three
NINA heaters were tested in parallel. The heating reaction was
initiated by adding 18 g of CaO to each NINA canister, followed by
6 mlofwater.The lidofeachcanisterwasthen sealedtocontainthe
exothermic reaction. After adding 200 ml of water to each of the
sample wells, temperature recording was initiated. Reaction tubes
wereaddedtothesamplewellsonceeachreactionchamberreached
a temperature of 58.5uC. For all samples incubated in the NINA
heater, 15 ml of mineral oil was added to the reaction tube during
the reaction mix preparation. The samples were incubated in the
heaters for a total of 60 minutes. All reactions were carried out in a
temperature-controlled laboratory with an ambient temperature of
28uC, unless otherwise stated. Following the amplification reaction,
the samples were incubated for two minutes in a heat block set to
80uC. After each amplification cycle, the temperature profile of
each device was analyzed by calculating the temperature mean,
standard deviation, median, minimum, and maximum from the
data provided by the DaqPRO 5300.
The stability of the NINA heaters at extreme low and high
temperatures was evaluated by placing the canisters in a
refrigerator set to 4uCo ra3 7 uC incubator during the length of
the amplification reaction. The temperature profiles were
recorded and compared to those of reactions that occurred at
the laboratory room temperature of 28uC.
Results
Evaluation of NINA heaters with HIV-specific RT-LAMP
assay
To determine the sensitivity of RT-LAMP reaction using RT-
specific primers, DNA and RNA linearity panels were tested in a
thermalcycler. The limit of detection for HIV-1 DNA was 10
Table 1. Sequence of HIV-1 reverse transcriptase-specific RT-
LAMP primers.
Primer name Sequence (59to 39)
F3 AGTTCCCTTAGATAAAGACTT
B3 CCTACATACAAATCATCCATGT
FIP GTGGAAGCACATTGTACTGATATCTTTTT
GGAAGTATACTGCATTTACCAT
BIP GGAAAGGATCACCAGCAATATTCCTCTGG
ATTTTGTTTTCTAAAAGGC
Loop F HEX-GGTGTCTCATTGTTTATACTA
Loop B GCATGACAAAAATCTTAGA
Quencher TAGTATAAACAATGAGACACC-BHQ1
doi:10.1371/journal.pone.0031432.t001
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containing 1700 copies/reaction was detected in all of the three
replicates, while the sample containing 140 copies/reaction was
detected in three out of five replicates (60%). For both DNA and
RNA linearity panels, the two samples nearest the limit of
detection were chosen to further evaluate the performance
consistency between the thermalcycler and NINA heaters. In
terms of positivity, the amplification results were consistent
between all three heaters and the thermalcycler (Table 2).
Since the RT-LAMP assay requires a constant temperature of
60uC for the length of the amplification reaction, the temperature
profiles of the sample wells were compared over the course of the
incubation and between all three NINA heaters. A representative
temperature profile is displayed in Figure 2, showing a steady
reaction temperature at or close to 60uC for length of
amplification reaction. During the 60 minute incubation, the
average temperature for each device was 60.2, 59.8, and 59.7
(Table 3). The minimum temperature achieved during the
reaction reflects the fact that the temperature of the sample port
dropped temporarily after the sample tubes are added to the
device, as shown in Figure 2. The maximum temperature of the
devices deviated from the desired reaction temperature of 60uCb y
less than one degree.
The ability of the NINA heaters to maintain a steady reaction
temperature in a wide range of ambient temperatures is essential
for POC testing, whether referring to an air-conditioned
laboratory or high-temperature field site. To evaluate the
performance of the NINA heaters at extreme low or high
temperatures, the canisters were placed in a 4uC refrigerator or
a3 7 uC incubator for the length of the amplification reaction. The
limit of detection for the DNA and RNA linearity panels was
similar to the results obtained in our temperature-controlled
laboratory (28uC; Table 2). The greatest degree of temperature
variation of the sample wells was observed at the ambient
temperature of 4uC (Table 3). The average temperature was
approximately two degrees lower than the desired reaction
temperature of 60uC. Additionally, the temperature of the devices
tended to decline from their steady state during the last 20 minutes
of the reaction (data not shown). The temperature profiles at the
ambient temperature of 37uC, however, were similar to those at
28uC.
Validation of NINA heaters with clinical specimens
Whole blood samples from HIV-1 infected individuals were
added directly into the RT-LAMP reaction and tested in the
NINA heaters. Positivity of the clinical specimens was consistent
between the thermalcycler and devices (Table 4). Amplification
consistency was most evident with two of the patient samples
(patient #4 and #5) that were only positive in one of the three
replicates, regardless of the heating device that was used. All HIV-
negative blood samples, included in each reaction, were negative
(data not shown). A representative experiment using the NINA
heaters is displayed in Figure 3, showing detection by agarose gel
and visual identification of fluorescence in the reaction tubes.
Table 2. Effect of ambient temperature on amplification
efficiency and reproducibility in NINA heaters.
NINA Heaters
286C4 6C3 7 6C
Sample
(copies/tube)
* Thermalcycler
{ 123123123
DNA (100) 3/3 +++++++++
DNA (10) 3/3 +++++++++
RNA (1700) 5/5 +++++++++
RNA (140) 3/5 2 ++++++++
*Calculated by accounting for the volume of each linearity panel member
added to the reaction tube.
{Number of positive samples/total number tested.
doi:10.1371/journal.pone.0031432.t002
Figure 2. Representative temperature profile of RT-LAMP reaction in NINA heater. The temperature of the reaction tube and phase
change material (PCM) was recorded for a 60 minute RT-LAMP reaction using the DaqPRO 5300. Temperature recording was initiated following
addition of water to the CaO and terminated upon sample removal.
doi:10.1371/journal.pone.0031432.g002
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In this study, we demonstrate the performance of portable,
inexpensive, non-instrumented nucleic acid (NINA) heaters for
amplification of HIV-1 using RT-LAMP. The isothermal
amplification reaction coupled with a device that generates heat
from an exothermic chemical reaction, as opposed to grid
electricity or battery power, comprises a point-of-care NAAT that
is practical for use in resource-limited settings. The heating devices
require minimal training and technical expertise to operate and
take approximately 10–15 minutes to reach a reaction tempera-
ture of 60uC once the chemical reaction has been initiated [27,28].
Furthermore, the temperature of the sample wells remain
relatively stable at the desired reaction temperature of 60uC
throughout the amplification reaction, as demonstrated by the
heating profiles and the consistency in amplification between the
devices and thermalcycler.
Since point-of-care testing may refer to an air-conditioned
laboratory or a field site with high temperatures and humidity, the
stability of the temperature generated by the heating devices must
be reliable. Though the temperature profiles at a representative
cold temperature of 4uC indicated a loss in reaction temperature
towards the end of the 60 minute incubation, the temperature
fluctuations were not significant enough to affect the amplification
reaction. Regardless, this thermal effect could be mitigated with
small modifications to the device to reduce heat loss at lower
temperatures. It should be possible to extend the temperature
range of the NINA heaters to 4uC and below by either adding a
larger quantity of heating mixture, better insulation, or both. Of
greater concern is the performance of the NINA heaters in high-
temperature field sites, where temperature control is not an option.
We demonstrate no difference in the temperature stability of the
NINA heaters and amplification consistency at an ambient
temperature of 37uC as compared to our temperature-controlled
laboratory.
For increased applicability for use at the POC, several
modifications can be made to the NINA heaters. The prototype
devices evaluated in this study contained only three sample wells;
however, up to 16 sample wells can be added to the lid of the
insulated canisters for a larger testing volume. In this study,
samples were removed from the NINA heaters after the
amplification reaction and heated for an additional two minutes
in an 80uC heat block to terminate the reaction. While the
additional heating step is not necessary to observe the amplified
products from extracted nucleic acid, the short, high-temperature
incubation facilitates the visual observation of the fluorescent label
in the whole blood samples. Modifications may be made to the
whole blood sample preparation method to eliminate the need for
the heating step. Alternatively, a second temperature-moderating
compartment can be added to the alternate end of the NINA
canisters, so the samples can be removed from the amplification
compartment and reinserted into the 80uC compartment. Lastly,
the DaqPRO data recorder was used in this study for validation
purposes only and would not be necessary for the final POC
product.
The feasibility of using LAMP as a diagnostic method in
resource-limited settings has been demonstrated for tuberculosis
Table 3. Effect of ambient temperature on stability and
reproducibility of reaction temperature in NINA heaters.
286C
* 46C
{ 376C
{
123123123
Mean 60.2 59.7 59.7 58.3 58.1 58.0 59.8 59.6 59.3
SD 0.4 0.5 0.4 1.0 0.7 1.0 0.7 0.5 0.4
Median 60.3 59.7 59.7 58.8 58.4 58.4 60.0 59.7 59.5
Minimum 58.4 56.9 57.1 55.1 55.9 54.9 57.7 57.8 57.8
Maximum 60.9 60.5 60.3 59.4 58.9 59.1 60.6 60.2 59.9
*Values are a mean of 8 independent reactions.
{Values are a mean of 2 independent reactions.
doi:10.1371/journal.pone.0031432.t003
Table 4. Amplification of HIV-1 DNA/RNA from whole blood
in NINA heaters.
Thermalcycler
* Device 1 Device 2 Device 3
Patient #1 3/3 +++
Patient #2 3/3 +++
Patient #3 3/3 +++
Patient #4 1/3 22+
Patient #5 1/3 2 + 2
Patient #6 3/3 +++
*Number of positive samples/total number tested.
doi:10.1371/journal.pone.0031432.t004
Figure 3. Validation of NINA heaters with clinical specimens.
The amplification results from a representative clinical specimen are
displayed in the figure. Whole blood from an HIV-1 infected patient was
added directly into the RT-LAMP reaction and amplification in all 3 NINA
heaters was compared. Amplified material was analyzed by (A) agarose
gel electrophoresis or (B) by observing fluorescence in the reaction
tubes under a UV light.
doi:10.1371/journal.pone.0031432.g003
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describe the use of reaction tubes pre-prepared with lyophilized
reaction mix. For POC use, limited sample manipulation and
reagent preparation is desired and, therefore, it is anticipated that
the test procedure of the end product will include reconstituting
the amplification reagents in water and adding the sample directly
into the reaction tube. We demonstrate the use of the NINA
heaters for amplification directly from whole blood specimens,
eliminating the need for a time-consuming, nucleic acid extraction
procedure and reducing the volume of sample needed for the
amplification reaction. A total volume of 10 ml of whole blood was
added to each reaction tube, which can easily be obtained by
finger-stick in settings where venipuncture is not feasible.
Additionally, our fluorescent detection method enables immediate
visualization of amplified products in the absence of specialized
equipment. To avoid cross-contamination of amplified material, it
is preferred that the reaction tubes remain closed post-amplifica-
tion. Future modifications will include optimizing the labeled-
primer/quencher sequences so that all components can be added
into the reaction mix prior to amplification. Due to availability, the
Bio-Rad ChemiDoc system was used as the UV source in this
study; however, an inexpensive keychain light would be more
suitable for naked-eye detection at the POC. For sensitive and
specific detection of diverse HIV-1 isolates, including non-B
subtypes, identification of the optimal primer set/sets is a key step
in the development of the RT-LAMP assay. Although all
experiments performed in this study involved subtype B standards
and specimens, ongoing research involves the continued develop-
ment and optimization of RT-LAMP primers based on regions of
the HIV-1 genome that are conserved among diverse subtypes.
Future studies will include large-scale evaluation of clinical
specimens with the optimized RT-LAMP assay and NINA device.
In summary, the RT-LAMP isothermal amplification method
used in conjunction with a simplified, chemical heating device
exhibits characteristics that are ideal for a rapid NAAT for POC
testing. The simplified, portable assay has the potential to fill an
important gap in HIV-1 diagnostics, providing immediate
knowledge or confirmation of HIV-1 infection status at the POC.
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